Champions Oncology (CSBR) vs MAIA Biotechnology (MAIA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Champions Oncology (CSBR) has outperformed MAIA Biotechnology (MAIA) over the past year, losing 23.0% versus a loss of 36.5%. MAIA Biotechnology is the larger company by market cap ($71.0 million vs $69.3 million), about 1.0 times the size. On valuation, MAIA Biotechnology trades at a lower forward P/E (1.0x vs 49.8x for Champions Oncology).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CSBR | MAIA |
|---|---|---|
| Share price | $4.98 | $1.15 |
| Market cap | $69.31M | $71.00M |
| 1-day change | +2.05% | -2.54% |
| YTD return | -27.93% | -24.84% |
| 1-year return | -23.03% | -36.46% |
| 5-year return | -50.60% | — |
| Forward P/E | 49.80 | 1.04 |
| EPS (TTM) | $-0.07 | $-0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.31 | $3.19 |
| 52-week low | $4.59 | $0.87 |
| Distance from 52-week high | -40.07% | -63.95% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +943.48% |
| Average volume | 11.33K | 527.89K |
| Shares outstanding | 13.92M | 61.74M |
| Employees | 214 | 13 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CSBR has outperformed MAIA by 13.4 percentage points over the past year.
About Champions Oncology
CSBR stock →Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform.
Healthcare · Biotechnology · 214 employees
About MAIA Biotechnology
MAIA stock →MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Healthcare · Biotechnology · 13 employees
CSBR vs MAIA FAQ
Which is bigger, Champions Oncology or MAIA Biotechnology?
MAIA Biotechnology (MAIA) is larger, with a market capitalization of $71.00M compared with $69.31M for Champions Oncology (CSBR).
Which stock has performed better over the past year, CSBR or MAIA?
CSBR returned -23.03% over the past 12 months, compared with -36.46% for MAIA (price return, excluding dividends). Past performance does not predict future results.
Are Champions Oncology and MAIA Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.